Recursion Pharmaceuticals (RXRX) Net Cash Flow Growth (1y) (2021 - 2026)
Recursion Pharmaceuticals (RXRX) Net Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Recursion Pharmaceuticals | 1.60 Bn | 944.55 Mn | -6.02 Mn | 13.97% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.97% |
| Dec 31, 2025 | -50.38% |
| Sep 30, 2025 | 377.72% |
| Jun 30, 2025 | -91.27% |
| Mar 31, 2025 | -3.83% |
| Dec 31, 2024 | 4,068.66% |
| Sep 30, 2024 | -142.67% |
| Jun 30, 2024 | 368.85% |
| Mar 31, 2024 | -23.88% |
| Dec 31, 2023 | -95.67% |
| Sep 30, 2023 | -2,600.26% |
| Jun 30, 2023 | -21.69% |
| Mar 31, 2023 | -134.44% |
| Dec 31, 2022 | 186.25% |
| Sep 30, 2022 | 100.33% |
| Jun 30, 2022 | -112.74% |
| Mar 31, 2022 | 563.76% |
| Dec 31, 2021 | -881.94% |
| Sep 30, 2021 | -215.07% |
| Jun 30, 2021 | 2,691.34% |